299 related articles for article (PubMed ID: 27328129)
21. Molecular mechanisms of polymyxin resistance and detection of mcr genes.
Mlynarcik P; Kolar M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Feb; 163(1):28-38. PubMed ID: 30439931
[TBL] [Abstract][Full Text] [Related]
22. Structure--activity relationships of polymyxin antibiotics.
Velkov T; Thompson PE; Nation RL; Li J
J Med Chem; 2010 Mar; 53(5):1898-916. PubMed ID: 19874036
[No Abstract] [Full Text] [Related]
23. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
[TBL] [Abstract][Full Text] [Related]
24. Causes of polymyxin treatment failure and new derivatives to fill the gap.
Chiu S; Hancock AM; Schofner BW; Sniezek KJ; Soto-Echevarria N; Leon G; Sivaloganathan DM; Wan X; Brynildsen MP
J Antibiot (Tokyo); 2022 Nov; 75(11):593-609. PubMed ID: 36123537
[TBL] [Abstract][Full Text] [Related]
25. Polymyxin: Alternative Mechanisms of Action and Resistance.
Trimble MJ; Mlynárčik P; Kolář M; Hancock RE
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27503996
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
Magee TV; Brown MF; Starr JT; Ackley DC; Abramite JA; Aubrecht J; Butler A; Crandon JL; Dib-Hajj F; Flanagan ME; Granskog K; Hardink JR; Huband MD; Irvine R; Kuhn M; Leach KL; Li B; Lin J; Luke DR; MacVane SH; Miller AA; McCurdy S; McKim JM; Nicolau DP; Nguyen TT; Noe MC; O'Donnell JP; Seibel SB; Shen Y; Stepan AF; Tomaras AP; Wilga PC; Zhang L; Xu J; Chen JM
J Med Chem; 2013 Jun; 56(12):5079-93. PubMed ID: 23735048
[TBL] [Abstract][Full Text] [Related]
27. PmxPred: A data-driven approach for the identification of active polymyxin analogues against gram-negative bacteria.
Wang X; Patil N; Li F; Wang Z; Zhan H; Schmidt D; Thompson P; Guo Y; Landersdorfer CB; Shen HH; Peleg AY; Li J; Song J
Comput Biol Med; 2024 Jan; 168():107681. PubMed ID: 37992470
[TBL] [Abstract][Full Text] [Related]
28. [Polymyxins - review with emphasis on nephrotoxicity].
Mendes CA; Burdmann EA
Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
[TBL] [Abstract][Full Text] [Related]
29. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.
Vaara M
Med Res Rev; 2018 Sep; 38(5):1661-1673. PubMed ID: 29485690
[TBL] [Abstract][Full Text] [Related]
30. Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity.
Patil NA; Ma W; Jiang X; He X; Yu HH; Wickremasinghe H; Wang J; Thompson PE; Velkov T; Roberts KD; Li J
J Med Chem; 2023 Feb; 66(4):2865-2876. PubMed ID: 36745479
[TBL] [Abstract][Full Text] [Related]
31. Ask the experts: how to curb antibiotic resistance and plug the antibiotics gap?
Piddock L; Garneau-Tsodikova S; Garner C
Future Med Chem; 2016 Jun; 8(10):1027-32. PubMed ID: 27327784
[No Abstract] [Full Text] [Related]
32. Synergistic combinations of polymyxins.
Lenhard JR; Nation RL; Tsuji BT
Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
[TBL] [Abstract][Full Text] [Related]
33. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
[TBL] [Abstract][Full Text] [Related]
34. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
35. Polymyxin antibiotics for gram-negative infections.
Arnold TM; Forrest GN; Messmer KJ
Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
[TBL] [Abstract][Full Text] [Related]
36. Multidrug-resistant gram-negative infections. Bringing back the old.
Chan-Tompkins NH
Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
[TBL] [Abstract][Full Text] [Related]
37. Resistance to polymyxins in Gram-negative organisms.
Jeannot K; Bolard A; Plésiat P
Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
[TBL] [Abstract][Full Text] [Related]
38. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
Baron S; Hadjadj L; Rolain JM; Olaitan AO
Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
[TBL] [Abstract][Full Text] [Related]
40. Agents of Last Resort: Polymyxin Resistance.
Kaye KS; Pogue JM; Tran TB; Nation RL; Li J
Infect Dis Clin North Am; 2016 Jun; 30(2):391-414. PubMed ID: 27208765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
